Project Grant P30GM154631
- Grant Award Summary The Medical University of South Carolina received a $415,250 Project Grant from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) for research investigating CD38 signaling in aging-associated immune responses induced by oral pathogens. The two-year award, effective May 1, 2025 through April 30, 2027, supports basic and translational research aimed at developing new therapeutic approaches...
- Federal Cooperative Agreement Award Summary The University of South Carolina received a $498,623 Cooperative Agreement from the National Center for Chronic Disease Prevention and Health Promotion (part of the Centers for Disease Control and Prevention) under the Diabetes Prevention and Control Programs (CFDA 93.988) effective September 30, 2025. The award, which extends through September 29, 2029, funds the project "Optimizing and Projecting Lifestyle Behavioral Interventions to Sustain...
- Federal Cooperative Agreement Summary The Salk Institute for Biological Studies received a $745,320 Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective September 1, 2025, through August 31, 2030. The award funds a five-year research initiative investigating the role of omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) in regulating inflammatory signals associated with pancreatic ductal adenocarcinoma...
- Federal Grant Award Summary The University of South Carolina received a $250,000 Project Grant from the National Science Foundation's Division of Engineering Education and Centers under the Engineering program (CFDA 47.041), effective August 1, 2025, through July 31, 2030. This award funds the Center for Rational Catalyst Synthesis (CERCAS) as a Phase III Industry/University Cooperative Research Center (IUCRC) with the university serving as the lead site. The center addresses fundamental...
- Federal Grant Award Summary The University of South Carolina received a $527,640 Project Grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), awarded August 15, 2025, with completion targeted for May 31, 2029. The grant supports the development of cationic metallopolymers designed to enhance antibiotic efficacy against multidrug-resistant (MDR)...
- Federal Grant Award Summary The University of South Carolina received a $256,929 Project Grant from the National Institutes of Health (NIH) Office of the Director under the Research Infrastructure Programs (CFDA 93.351) to establish a state-of-the-art 3D bioprinting shared facility. The award, made effective August 15, 2025, with a one-year performance period through August 14, 2026, supports the acquisition and installation of an advanced CELLINK bioprinting system comprising three core...
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $466,125 Project Grant from the National Center for Complementary and Integrative Health (NCCIH) under the Research and Training in Complementary and Integrative Health program (CFDA 93.213), effective September 1, 2025, through August 31, 2027. This award supports fundamental research investigating the mechanisms by which polyunsaturated fatty acids (PUFAs) regulate gene expression, specifically examining...
- Federal Grant Award Summary The National Institutes of Health (NIH) Office of the Director awarded the University of South Carolina $749,362 under the Research Infrastructure Programs (CFDA 93.351) to acquire a ZEISS LSM 980 confocal microscope with Airyscan2 capabilities for biological research. The award, effective August 1, 2025, through July 31, 2026, funds the procurement and deployment of advanced microscopy instrumentation designed to replace the institution's aging ZEISS LSM 700...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of South Carolina a Project Grant of $223,500 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct investigative research on mast cell regulation and inflammation. The research, initiated August 6, 2025, and concluding July 31, 2027, focuses on understanding how the ITCH ubiquitin ligase regulates mast cell functions independent of FcεRI-mediated...
- Summary Columbia University's Health Sciences Division received a $727,904 Cooperative Agreement award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) on August 11, 2025, for research on engineered probiotic bacteria to prevent and intercept colorectal cancer (CRC). The award supports a two-phase UG3/UH3 project designed to develop and characterize engineered strains of Escherichia coli Nissle 1917 (ECN) that selectively colonize precancerous lesions...
CENTER FOR DIETARY SUPPLEMENTS AND INFLAMMATION (CDSI) COBRE - OVERALL ABSTRACT THE CENTER FOR DIETARY SUPPLEMENTS AND INFLAMMATION (CDSI) COBRE IS LOCATED AT THE SCHOOL OF MEDICINE (SOM), THE UNIVERSITY OF SOUTH CAROLINA (USC), COLUMBIA, SC. SOM IS ONE OF THE SMALLEST MEDICAL SCHOOLS IN THE NATION LOCATED AT THE VETERANS ADMINISTRATION (VA) CAMPUS. THUS, THE CDSI ATTRACTS USERS FROM MULTIPLE COLLEGES ACROSS USC. THE SCIENTIFIC MISSION OF THE CDSI IS TO INVESTIGATE HOW COMPOUNDS DERIVED FROM BOTANICALS AND NATURAL PRODUCTS CAN ATTENUATE INFLAMMATION AS WELL AS UNDERSTAND THE MECHANISMS THAT TRIGGER CHRONIC INFLAMMATORY DISEASES. INFLAMMATION PLAYS A CRITICAL ROLE IN THE PATHOGENESIS OF NOT ONLY AUTOIMMUNE DISEASES BUT ALSO A WIDE RANGE OF CLINICAL DISORDERS INCLUDING CARDIOVASCULAR DISEASES, NEURODEGENERATIVE DISORDERS, OBESITY, AGING, AND CANCER. THUS, UNDERSTANDING THE MODE OF ACTION OF BOTANICALS OR THEIR CONSTITUENTS ON INFLAMMATION COULD LEAD TO NOVEL TREATMENT MODALITIES WITH FAR-RANGING CLINICAL IMPLICATIONS. TO ACCOMPLISH THIS GOAL, WE WILL CONTINUE TO BUILD ON THE SUCCESS OF COBRE PHASE-1 AND PHASE-2, FURTHER ADVANCE THE RESEARCH INFRASTRUCTURE, GROW THE CRITICAL MASS OF RESEARCHERS USING DIVERSE PERSPECTIVES, AND PROMOTE THE SUSTAINABILITY OF THE RESEARCH CORES. IN PHASES-1 AND 2, WE HAVE MADE OUTSTANDING PROGRESS IN THE SUCCESSFUL TRANSITION OF 12 OF OUR JUNIOR FACULTY RESEARCH PROJECT LEADERS (RPLS) INTO INDEPENDENT NIH/NSF-FUNDED INVESTIGATORS AS PIS. ADDITIONALLY, THE CDSI FUNDED 26 PILOT PROJECT LEADERS (PPLS) WHO WERE ALSO HIGHLY PRODUCTIVE. ALSO, WE WERE SUCCESSFUL IN SECURING NIH COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) CENTER (PPG/P01) FOR EPIGENETIC REGULATION OF INFLAMMATION, IN WHICH 'GRADUATED' RPLS SERVED AS PROJECT LEADERS, THEREBY PAVING THE PATH TOWARDS SUSTAINABILITY OF CDSI. THE SPECIFIC AIMS INCLUDE: 1) TO SUPPORT INNOVATIVE RESEARCH USING THE LATEST TECHNOLOGIES AND EQUIPMENT SUCH AS SPECTRAL FLOW CYTOMETRY, SINGLE-CELL RNA-SEQ AND SINGLE-CELL SPATIAL TRANSCRIPTOMICS, NATURAL PRODUCT LIBRARY, AND HIGH-THROUGHPUT DATA ANALYSIS, OFFERED AT OUR CORE FACILITIES. 2) TO CONTINUE TO GROW THE CRITICAL MASS OF RESEARCHERS AT CDSI BY PROVIDING SUPPORT THROUGH THE PILOT PROJECT PROGRAM (PPP) AND RECRUITMENT OF NEW AND EARLY-STAGE AS WELL AS DIVERSE INVESTIGATORS. 3) TO SUSTAIN A MULTI-DISCIPLINARY, COLLABORATIVE RESEARCH PROGRAM AND CORES BEYOND PHASE-3. THE CDSI WILL OFFER TWO STATE-OF-THE-ART RESEARCH CORE FACILITIES THAT INCLUDE A FLOW CYTOMETRY, AND CELL ANALYSIS (FCCA) CORE, AND A BIOANALYTICAL CORE, TO STUDY EPIGENETIC AND MICROBIOME REGULATION OF INFLAMMATION. THE PROGRAM WILL BE EVALUATED BY AN ADMINISTRATIVE CORE (AC) CONSISTING OF NATIONALLY RECOGNIZED SCIENTISTS. ADDITIONALLY, THROUGH INSTITUTIONAL SUPPORT, SEVERAL NEW TENURE- TRACK AND DIVERSE FACULTY WILL BE RECRUITED AND MENTORED AT USC TO FURTHER INCREASE THE CRITICAL MASS OF USERS. THE LONG-TERM OBJECTIVE OF THE CDSI IS TO BUILD A SELF-SUSTAINING, NATIONALLY AND INTERNATIONALLY RECOGNIZED MULTI- DISCIPLINARY CENTER FOR DIETARY SUPPLEMENTS AND INFLAMMATION RESEARCH.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.1m | 9/3/25 | ||
| Not listed | $1.1m | 7/11/24 |